Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
The company was incorporated in 2012 and is based in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -2.28 Decreased by -7.70 K% | -0.20 Decreased by -1.04 K% |
| Mar 27, 24 | -0.04 Increased by +78.95% | -0.10 Increased by +60.00% |
| Nov 2, 23 | -0.09 Decreased by -152.94% | -0.16 Increased by +43.75% |
| Aug 3, 23 | -0.14 Increased by +26.32% | -0.13 Decreased by -7.69% |
| May 11, 23 | 0.03 Increased by +111.11% | -0.04 Increased by +175.00% |
| Mar 23, 23 | -0.19 Increased by +26.92% | -0.17 Decreased by -11.76% |
| Nov 3, 22 | 0.17 Increased by +145.95% | 0.18 Decreased by -5.56% |
| Aug 9, 22 | -0.19 Decreased by -205.56% | -0.28 Increased by +32.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 12.72 M Decreased by -68.79% | -8.17 M Decreased by -154.56% | Decreased by -64.26% Decreased by -274.79% |
| Jun 30, 23 | 7.61 M Increased by +22.49% | -12.36 M Increased by +5.85% | Decreased by -162.29% Increased by +23.14% |
| Mar 31, 23 | 25.99 M Increased by +265.59% | 3.21 M Increased by +117.53% | Increased by +12.35% Increased by +104.80% |
| Dec 31, 22 | 10.22 M Increased by +41.44% | -13.38 M Increased by +20.39% | Decreased by -130.90% Increased by +43.71% |
| Sep 30, 22 | 40.74 M Increased by +475.81% | 14.98 M Increased by +182.83% | Increased by +36.76% Increased by +114.38% |
| Jun 30, 22 | 6.22 M Decreased by -81.09% | -13.13 M Decreased by -222.54% | Decreased by -211.15% Decreased by -747.84% |
| Mar 31, 22 | 7.11 M Increased by +195.22% | -18.30 M Decreased by -0.05% | Decreased by -257.43% Increased by +66.11% |
| Dec 31, 21 | 7.22 M Increased by +93.75% | -16.80 M Increased by +22.33% | Decreased by -232.57% Increased by +59.91% |